Time-trend Analysis of Clinical Characteristic and Outcomes in Patients With Unprotected Left Main Coronary Artery Disease Treated With PCI Over a 10-year Period

The Chinese University of Hong Kong

Status: Active, not recruiting

Conditions: Cardiovascular Diseases

Treatments: Device: The AngioliteTM Durable Fluoroacrylate Polymer-based Sirolimus-Eluting Stent

Study type: Interventional

Funder types: Other

Identifiers

NCT05548023

2023.464

Details and patient eligibility

About

Surgical coronary bypass surgery (CABG) has been demonstrated to confer significant survival benefit over medical therapies patients with LMCA in earlier clinical trials1,2,3 and therefore was the revascularization modality of choice for a long time. Recently, several randomized controlled trials and meta-analyses have shown percutaneous coronary intervention (PCI) to be non-inferior to CABG in the treatment of LMCA disease4,5,6,7,8. PCI is now considered to be an appropriate alternative to CABG for LMCA disease in patients with suitable anatomy9,10. Over recent decades, LMCA PCI has been performed in patients with increasing anatomical complexity and higher risk profiles (e.g. elderly, heart failure, renal failure etc). 11,12. In recent years, remarkable advancement in interventional techniques and technologies such as 2nd/3rd generation DES and potent antiplatelet therapy have contributed to the improvement of PCI success rates and reduction in complications and adverse events. Knowledge related to long term temporal variation of clinical and procedural characteristics and outcomes in patients with LMCA disease treated with PCI will therefore be important to inform and define future treatment strategies. This proposal aims to evaluate time-trends and regional differences in clinical characteristics and outcomes of patients with LMCA disease treated with PCI in the Asia-Pacific region

Enrollment: 500 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Lp(a) ≥ 70 mg/dL at the screening visit
• Optimal LDL-cholesterol lowering treatment
• Optimal treatment of other CV risk factors
• Myocardial infarction: ≥ 3 months to ≤ 10 years prior to the screening visit, and/or
• Ischemic stroke: ≥ 3 months to ≤ 10 years prior to the screening visit, and/or
• Clinically significant symptomatic peripheral artery disease

Exclusion criteria

• Uncontrolled hypertension
• Heart failure New York Heart Association (NYHA) class IV
• History of malignancy of any organ system
• History of hemorrhagic stroke or other major bleeding
• Platelet count <140,000 per μL
• Active liver disease or hepatic dysfunction

Trial design

Primary purpose: Other

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

500 participants in 1 patient group

unprotected left main coronary artery disease treated with PCI

Other group

Treatment:

Device: The AngioliteTM Durable Fluoroacrylate Polymer-based Sirolimus-Eluting Stent